Literature DB >> 10230458

HIT '91 (prospective, co-operative study for the treatment of malignant brain tumors in childhood): accuracy and acute toxicity of the irradiation of the craniospinal axis. Results of the quality assurance program.

R D Kortmann1, B Timmermann, J Kühl, N Willich, M Flentje, C Meisner, M Bamberg.   

Abstract

BACKGROUND: It was the aim of the quality control program of the randomized trial HIT '91 (intensive chemotherapy before irradiation versus maintenance chemotherapy after irradiation) to assess prospectively the quality of neuroaxis irradiation with respect to the protocol guidelines and to evaluate acute toxicity with respect to treatment arm. PATIENTS,
MATERIALS AND METHODS: Data of 134 patients undergoing irradiation of the craniospinal axis were available. Positioning aids, shielding techniques, treatment machines, choice of energy, total dose and fractionation were evaluated. A total of 651 simulation and verification films were analyzed to assess the coverage of the clinical target volume (whole brain, posterior fossa, sacral nerve roots) and deviations of field alignment between simulation and verification of first treatment. Field matching between whole brain and adjacent cranial spinal fields was analyzed with respect to site and width of junction. Acute maximal side effects were evaluated according to a modified WHO score for neurotoxicity, infections, skin, mucosa and myelotoxicity.
RESULTS: In 91.3% of patients contemporary positioning aids and individualized shielding techniques were used to assure a reproducible treatment. In 98 patients (73.1%) linear accelerators and in 36 patients (26.8%) Cobalt machines were used. Single and total dose were administered according to the protocol guidelines in more than 90% of patients. In 20.2% of patients the cribriform plate, in 1.4% the middle cranial fossa and in 21.1% the posterior fossa and in 4.5% the 2nd sacral segment were incompletely encompassed by the treatment portals. Ninety-five percent of deviations of field alignment were less than 13.0 mm (whole brain) and 12 mm (cranial spinal field) with a random error between 4.9 and 7.6 mm (whole brain) and 6.9 mm and 9.9 mm (spinal canal), respectively. In 77.5% of patients the junctions between whole brain and cranial spinal fields were placed without a gap. A gap between 5 and 10 mm was left in 15 patients (18.7%), exceeding 10 mm in 3 patients. Acute neurotoxicity and skin reactions were mild, the rate of infections was low in both treatment arms. However, myelotoxicity resulted in interruptions of radiotherapy in 31.9% after intensive chemotherapy as compared to 20.0% without preceding chemotherapy.
CONCLUSIONS: In the HIT '91 trial a precise radiotherapy of craniospinal axis has been performed in the majority of patients. Our findings indicate that the high quality is possibly an important contributing factor for the therapeutic outcome. However, preceding intensive chemotherapy caused marked toxicity of subsequent irradiation leading to a high rate of interruptions. Our database is subject to a future analysis of recurrences.

Entities:  

Mesh:

Year:  1999        PMID: 10230458     DOI: 10.1007/bf02742358

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  22 in total

1.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

2.  Accuracy of field alignment in radiotherapy of head and neck cancer utilizing individualized face mask immobilization: a retrospective analysis of clinical practice.

Authors:  C F Hess; R D Kortmann; R Jany; A Hamberger; M Bamberg
Journal:  Radiother Oncol       Date:  1995-01       Impact factor: 6.280

3.  Concerning the inferior portion of the spinal radiotherapy field for malignancies that disseminate via the cerebrospinal fluid.

Authors:  E C Halperin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-05-20       Impact factor: 7.038

4.  Radiation for medulloblastoma adjusted to prevent recurrence to the cribriform plate region.

Authors:  B Jereb; S Krishnaswami; A Reid; J C Allen
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

5.  [Therapy and prognosis of the medulloblastoma: progress through late irradiation techniques (author's transl)].

Authors:  M Bamberg; G Schmitt; U Quast; E B Bongartz; H E Nau; C Bayindir; V Reinhardt
Journal:  Strahlentherapie       Date:  1980-01

6.  Improved methods for determination of variability in patient positioning for radiation therapy using simulation and serial portal film measurements.

Authors:  S A Rosenthal; J M Galvin; J W Goldwein; A R Smith; P H Blitzer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  CNS-85 trial: a cooperative pediatric CNS tumor study--results of treatment of medulloblastoma patients.

Authors:  S Pezzotta; L Cordero di Montezemolo; R Knerich; M Arrigoni; A Barbara; L Besenzon; A Brach del Prever; P Fidani; D Locatelli; G Loiacono; L Magrassi; G Perilongo; L Rigobello; A Urgesi; E Madon
Journal:  Childs Nerv Syst       Date:  1996-02       Impact factor: 1.475

8.  Spontaneous seeding of medulloblastoma: results of cerebrospinal fluid cytology and arachnoid biopsy from the cisterna magna.

Authors:  T Tomita; D G McLone
Journal:  Neurosurgery       Date:  1983-03       Impact factor: 4.654

9.  Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89.

Authors:  J Kühl; H L Müller; F Berthold; R D Kortmann; F Deinlein; E Maass; N Graf; A Gnekow; W Scheurlen; U Göbel; J E Wolff; M Bamberg; P Kaatsch; P Kleihues; D Rating; N Sörensen; O D Wiestler
Journal:  Klin Padiatr       Date:  1998 Jul-Aug       Impact factor: 1.349

10.  Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.

Authors:  C C Bailey; A Gnekow; S Wellek; M Jones; C Round; J Brown; A Phillips; M K Neidhardt
Journal:  Med Pediatr Oncol       Date:  1995-09
View more
  2 in total

1.  Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma : First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial.

Authors:  Stefan Dietzsch; Annett Braesigk; Clemens Seidel; Julia Remmele; Ralf Kitzing; Tina Schlender; Martin Mynarek; Dirk Geismar; Karolina Jablonska; Rudolf Schwarz; Montserrat Pazos; Marc Walser; Silke Frick; Kristin Gurtner; Christiane Matuschek; Semi Ben Harrabi; Albrecht Glück; Victor Lewitzki; Karin Dieckmann; Martin Benesch; Nicolas U Gerber; Stefan Rutkowski; Beate Timmermann; Rolf-Dieter Kortmann
Journal:  Strahlenther Onkol       Date:  2020-11-23       Impact factor: 3.621

Review 2.  Radiotherapy in Medulloblastoma-Evolution of Treatment, Current Concepts and Future Perspectives.

Authors:  Clemens Seidel; Sina Heider; Peter Hau; Annegret Glasow; Stefan Dietzsch; Rolf-Dieter Kortmann
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.